Alto Neuroscience (ANRO) CEO awarded 306,000 stock options at $16.71

Rhea-AI Filing Summary

Alto Neuroscience reported that President and CEO Etkin Amit received an employee stock option grant on February 11, 2026. The option covers 306,000 shares of common stock at an exercise price of $16.71 per share and expires on February 10, 2036.

According to the vesting terms, 25% of the shares vest on February 11, 2027, with the remaining shares vesting in equal monthly installments over the following three years, contingent on his continued service. After this award, Amit directly holds options for 306,000 shares.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Etkin Amit

Role PRESIDENT AND CEO

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (Right to Buy)	306,000	$0.00	--

Holdings After Transaction: Employee Stock Option (Right to Buy) — 306,000 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Etkin Amit

(Last) (First) (Middle)

C/O ALTO NEUROSCIENCE, INC.

650 CASTRO STREET, SUITE 450

(Street)

MOUTAIN VIEW CA 94041

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Alto Neuroscience, Inc. [ ANRO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	PRESIDENT AND CEO

3. Date of Earliest Transaction (Month/Day/Year)
02/11/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	$16.71	02/11/2026		A		306,000		(1)	02/10/2036	Common Stock	306,000	$0	306,000	D

Explanation of Responses:

1. 25% of the shares underlying the option shall vest on February 11, 2027, and one forty-eighth (1/48th) of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date.

Remarks:

	/s/ Erin R. McQuade, Attorney-in-Fact	02/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Alto Neuroscience (ANRO) disclose about CEO Etkin Amit’s stock options?

Alto Neuroscience disclosed that CEO Etkin Amit received an employee stock option grant for 306,000 shares on February 11, 2026. The option allows him to buy common stock at an exercise price of $16.71 per share, subject to a multi-year vesting schedule.

What is the size and exercise price of the new Alto Neuroscience (ANRO) CEO option grant?

The new grant to CEO Etkin Amit covers 306,000 stock options with an exercise price of $16.71 per share. These options give him the right to purchase Alto Neuroscience common stock at that fixed price if and when the options vest and are exercised.

How do Etkin Amit’s Alto Neuroscience (ANRO) stock options vest over time?

The options vest over four years. 25% of the shares vest on February 11, 2027, and the remaining 75% vest in equal monthly installments thereafter, as long as Amit continues to provide service to Alto Neuroscience on each vesting date.

When do the newly granted Alto Neuroscience (ANRO) CEO options expire?

The employee stock options granted to CEO Etkin Amit expire on February 10, 2036. This expiration date defines the last day he may exercise the options, assuming they have vested and other standard conditions for exercise are satisfied.

How many Alto Neuroscience (ANRO) derivative securities does CEO Etkin Amit now hold?

Following the reported transaction, CEO Etkin Amit beneficially owns 306,000 derivative securities, all held directly. These represent employee stock options tied to Alto Neuroscience common stock, subject to the specified vesting schedule and the option’s February 10, 2036 expiration.

What type of transaction was reported in Alto Neuroscience (ANRO) CEO’s Form 4?

The Form 4 reports an acquisition of a derivative security, specifically an employee stock option grant. It is coded as a grant, award, or other acquisition, indicating the options were awarded to CEO Etkin Amit rather than bought in an open-market purchase.